2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. iGluR
  4. GYKI 53405

GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia.

For research use only. We do not sell to patients.

GYKI 53405

GYKI 53405 Chemical Structure

CAS No. : 143691-37-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

GYKI 53405 Related Antibodies

Top Publications Citing Use of Products

View All iGluR Isoform Specific Products:

View All Isoforms
AMPA Receptor NMDA Receptor Kainate Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABAA, GABAB or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia[1][2][3].

IC50 & Target[2]

AMPA Receptor

 

In Vitro

GYKI 53405 inhibits kainate-induced whole-cell currents in primary cultured embryonic telencephalic cells of Sprague-Dawley rats, with an IC50 of 7.4 μM[2].
GYKI 53405 inhibits the amplitude of AMPA receptor-mediated population spike potentials in CA1 pyramidal cells of hippocampal slices from male Wistar rats, with an IC50 of 17.8 μM[2].
GYKI 53405 (10-7 M) exhibits no significant binding affinity for GABAA, GABAB or benzodiazepine receptors at a concentration of 10-7 M[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GYKI 53405 Related Antibodies
In Vivo

GYKI 53405 (16 mg/kg; i.p.; single administration) fails to significantly alter spike-and-wave discharges and wakefulness in WAG/Rij rats with genetic absence epilepsy, nor does it induce adverse neurobehavioral effects[1].
GYKI 53405 (3 mg/kg; p.o.; single dose) induces anxiolytic-like behavior in male Sprague-Dawley rats in the elevated plus maze test[2].
GYKI 53405 (3 mg/kg; i.p.; single administration) reverses mCPP-induced anxiety-like behavior in male Wistar rats in the light-dark box test[2].
Oral administration of GYKI 53405 produces sedative effects in male NMRI mice, with an ID50 of 9.8 mg/kg[2].
GYKI 53405 (i.p.; single administration) exhibits potent anticonvulsant activity in audiogenic seizure-susceptible DBA/2j mice, with an ED50 value of 1.1 mg/kg for inhibiting tonic extension seizures and an ED50 value of 3.1 mg/kg for inhibiting clonic seizures[3].
GYKI 53405 (i.p.; single dose; 30 min prior to electroshock) inhibits maximal electroshock-induced tonic hindlimb extension seizures in NMRI mice, with an i.p. ED50 of 2.6 mg/kg[3].
GYKI 53405 (3.75-30 mg/kg; i.p.; single administration; 30 minutes prior to MgCl2 injection) exerts dose-dependent neuroprotective activity in the MgCl2-induced global cerebral ischemia model of NMRI mice, with a PD50 of 8.3 mg/kg via intraperitoneal injection, and significantly prolongs the survival time of mice starting from the dose of 7.5 mg/kg[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: WAG/Rij (male, 7-8 months old, 320-420 g, genetic absence epilepsy model)[1]
Dosage: 16 mg/kg
Administration: i.p.; single dose
Result: Failed to significantly alter cumulative duration, number, or proportional occurrence of spike-wave discharges during light slow wave sleep compared to vehicle-treated controls.
Failed to significantly alter vigilance states (wakefulness, light slow wave sleep, deep slow wave sleep) compared to vehicle-treated controls.
Failed to significantly alter average paroxysm duration compared to vehicle-treated controls.
Increased frequency of self-grooming compared to vehicle-treated controls.
Induced wet dog shakes in 3 of 8 animals.
Slightly reduced locomotor activity compared to vehicle-treated controls.
Did not induce abnormal behavior or ataxia.
Animal Model: Sprague-Dawley (male, 220-250 g)[2]
Dosage: 3 mg/kg
Administration: p.o.; single dose
Result: Significantly increased the time rats spent in the open arms of the elevated plus-maze.
Animal Model: Wistar (male, 180-220 g)[2]
Dosage: 3 mg/kg
Administration: i.p.; single dose
Result: Significantly reversed the mCPP-induced reduction in movement time in the lit area of the light-dark box.
Animal Model: NMRI (male, 20-25 g)[2]
Dosage: 1 mg/kg; 9.8 mg/kg
Administration: p.o.; single dose
Result: Defined the maximal non-sedating dose as 1 mg/kg p.o.
Produced sedative inhibition of spontaneous motor activity at doses above 1 mg/kg p.o., with an ID50 of 9.8 mg/kg p.o.
Animal Model: DBA/2j (male, 7-11 g, audiogenic seizure model)[3]
Dosage: 1.1 mg/kg (tonic extensor seizure inhibition); 3.1 mg/kg (clonic seizure inhibition); 5 mg/kg (time-course assessment); over 2.5 mg/kg (tonic fits and death prevention)
Administration: i.p.; single dose; 15 minutes prior to seizure challenge (for dose-response); single dose (for time-course assessment)
Result: Achieved an ED50 of 1.1 mg/kg for inhibition of tonic extensor seizures.
Achieved an ED50 of 3.1 mg/kg for inhibition of clonic seizures.
Completely prevented tonic fits and death at doses over 2.5 mg/kg.
Showed more than 80% seizure suppression 3 hours after treatment at 5 mg/kg.
Exhibited strong anticonvulsive effect that gradually disappeared between 3 and 8 hours at 5 mg/kg.
Sustained maximal exit inhibition effect for 4 hours, then gradually decreased to zero between 4 and 8 hours at 5 mg/kg.
Animal Model: NMRI (Crl: NMRI BR-outbread, male, 20-25 g, maximal electroshock seizure model)[3]
Dosage: 2.6 mg/kg
Administration: i.p.; single dose; 30 minutes prior to electroshock
Result: Achieved an ED50 of 2.6 mg/kg for inhibition of tonic hind limb extensor seizures.
Animal Model: NMRI (Crl: NMRI BR-outbread, male, 20-25 g, MgCl2-induced global cerebral ischaemia model)[3]
Dosage: 3.75 mg/kg; 7.5 mg/kg; 15 mg/kg; 30 mg/kg; 8.3 mg/kg (PD50 dose)
Administration: i.p.; single dose; 30 minutes prior to MgCl2 injection
Result: Prolonged survival time in a dose-dependent manner, with a PD50 of 8.3 mg/kg.
Produced significant increases in survival time at doses of 7.5 mg/kg and above.
Molecular Weight

337.38

Formula

C19H19N3O3
CAS No.
SMILES

O=C(N1N=C(C=2C=CC(N)=CC2)C=3C=C4OCOC4=CC3CC1C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

GYKI 53405 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

GYKI 53405143691-37-6LY 293606GYKI53405GYKI-53405LY293606LY-293606iGluRIonotropic glutamate receptorsAMPA receptorWistar rat hippocampal slicesDBA/2j miceGABA_A receptorsGABA_B receptorsCA1 pyramidal cellsWAG/Rij ratsbenzodiazepine receptorsNMRI miceSprague-Dawley rat embryo telencephalon cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
GYKI 53405
Cat. No.:
HY-15080
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.